View Older Stories View More Recent Stories

Jun 7, 2021 06:45AM New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial
Jun 3, 2021 05:02PM Merck (MRK) KEYTRUDA Reduced the Risk of Disease Recurrence or Death by 32% in RCC
Jun 3, 2021 05:00PM LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Br
Jun 3, 2021 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
Jun 3, 2021 06:48AM Merck (MRK) Announces Completion of Organon & Co. (OGN) Spinoff
Jun 3, 2021 06:45AM Merck Announces Completion of Organon & Co. Spinoff
Jun 1, 2021 06:48AM Sanofi (SNY) and Merck's (MRK) first and only six-in-one pediatric combination vaccine now available in the United States
Jun 1, 2021 06:45AM Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
Jun 1, 2021 06:45AM Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
May 26, 2021 08:00AM MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid-19 Demand
May 25, 2021 02:04PM Merck Announces Third-Quarter 2021 Dividend
May 24, 2021 06:46AM Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy
May 24, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesoph
May 20, 2021 06:47AM Merck (MRK) Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Va
May 20, 2021 06:45AM Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
May 17, 2021 07:00AM Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations
May 13, 2021 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC
May 13, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
May 12, 2021 07:05AM IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 7, 2021 01:05PM Merck (MRK) Declares Record Date and Dividend for the Organon & Co. Spinoff
May 7, 2021 01:01PM Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
May 6, 2021 06:59AM Merck (MRK), Eisai Receive Priority Review From FDA for KEYTRUDA Plus LENVIMA Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
May 6, 2021 06:45AM Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
May 6, 2021 06:30AM Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
May 5, 2021 05:26PM Merck (MRK) Announces FDA Approves KEYTRUDA Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal
May 5, 2021 04:05PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesoph
May 3, 2021 06:45AM Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
Apr 29, 2021 06:30AM Merck Announces First-Quarter 2021 Financial Results
Apr 27, 2021 06:47AM Merck to Hold Investor Briefing Featuring Organon on May 3
Apr 27, 2021 06:45AM Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Ora
Apr 26, 2021 06:45AM Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
Apr 15, 2021 06:49AM Merck (MRK), Ridgeback Biotherapeutics announce data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate clinical benefit in hospitalized Covid-19 patients
Apr 15, 2021 06:46AM Merck (MRK) to Discontinue Development of MK-7110 for COVID-19
Apr 15, 2021 06:46AM Merck to Discontinue Development of MK-7110 for COVID-19
Apr 15, 2021 06:45AM Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
Apr 14, 2021 08:00AM Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
Apr 8, 2021 06:46AM Merck's (MRK) KEYTRUDA Demonstrated Superior Disease-Free Survival Compared With Placebo as Adjuvant Therapy in Patients With RCC Following Surgery
Apr 8, 2021 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (DFS) Compared With Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC) Following Surgery
Apr 7, 2021 07:10AM IMV Inc. (IMV) Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck (MRK) Following Feedback from FDA
Apr 1, 2021 08:35AM Merck (MRK) Completes Acquisition of Pandion Therapeutics (PAND)
Apr 1, 2021 08:30AM Merck Completes Acquisition of Pandion Therapeutics
Mar 30, 2021 07:34AM Merck (MRK) Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 07:30AM Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon
Mar 30, 2021 06:46AM Merck (MRK) Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial Can
Mar 30, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Ur
Mar 29, 2021 04:16PM Merck (MRK) Receives CRL From US FDA for Supplemental Biologics License Application for KEYTRUDA in High-Risk Early-Stage TNBC
Mar 29, 2021 04:15PM Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Mar 29, 2021 06:45AM Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29
Mar 24, 2021 06:45AM Merck (MRK) Appoints Caroline Litchfield as CFO
Mar 24, 2021 06:45AM Merck Appoints Caroline Litchfield Chief Financial Officer
View More Recent Stories View Older Stories